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Introduction 
As humans continue to live longer, a central concern is to find ways to maintain their health 
during the extra years of life. Immunity declines during ageing and this is highlighted by the 
increased susceptibility to infection induced by previously encountered [1, 2] as well as new 
emerging pathogens [3-5] and also decreased ability to respond to vaccination [6]. It is therefore 
crucial to understand mechanisms that are responsible for this age-associated decrease in 
immunity and to develop new strategies to enhance immune function to reduce infections and 
the related consequences of reduced health in older humans. In this article, we discuss how the 
induction of senescence alters the function of leukocytes, in particular T cells. An emerging 
concept is that senescence and nutrient sensing signalling pathways within T cells converge to 
regulate functional responses. Furthermore the inhibition of these signalling pathways can 
enhance T cell function is a reason to be optimistic in the search of ways to enhance immunity 
during ageing.  
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What is senescence? 
The word senescence is defined by the Oxford English Dictionary as “The process or condition 
of growing old “. Cellular senescence was first described in fibroblasts by Leonard Hayflick who 
with co-workers showed that fibroblasts have a finite capacity to replicate when cultured in vitro, 
after which they stop dividing but remain metabolically active for extended periods [7]. This 
constraint on the excessive proliferative activity, i.e. “growing old” of fibroblasts in tissue culture, 
is known as the Hayflick Limit, that is widely considered to be an anti-cancer mechanism [8]. It 
was subsequently shown that the molecular basis for the Hayflick Limit is the erosion of 
telomeres, repeating hexameric DNA sequences at the ends of chromosomes, that occurs each 
time a cell divides and has been described extensively elsewhere [9-11]. Short telomeres are 
interpreted as DNA damage by cell sensing machinery that initiates a cascade of events that 
culminates in growth arrest (reviewed in Akbar and Henson 2011 [12]). Cellular senescence can 
also result independently of telomere attrition, when there is actual damage to DNA that can 
occur anywhere in the genome and this also activates a brake on cellular proliferation [13, 14]. 
The intracellular sensing of DNA damage leads to the initiation of DNA repair, which, if 
successful, enables the cell to continue its existence. If the DNA cannot be repaired, DNA 
damage repair foci persist within the nucleus, leading ultimately to growth arrest or senescence. 
The molecules involved in the DNA repair and the signaling processes that shut down cellular 
proliferation have been described in detail previously [15, 16].While the limit to the extent of 
proliferation of cells that have damaged DNA is considered to be a natural defense against 
malignancy, the accumulation of senescent cells is associated with the ageing of tissues [17, 
18].  
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 In this article, we will highlight recent information on the signalling processes that are involved 
in senescence associated proliferative arrest in T cells, consider the potential impact of 
accumulation of senescent T cells on immunity during ageing and discuss ways by which 
proliferative activity may be reconstituted in these cells with the aim of enhancing immunity. 
 
What is T cell senescence? 
There is a central role for proliferation of antigen-specific T and B cells in the maintenance of 
immune memory [19, 20]. The restriction to the extent of proliferation of T cells, especially those 
that are specific for frequently encountered or persistent antigens may therefore compromise 
the maintenance of specific immunity in older humans as they may be driven towards 
senescence [1, 12]. Furthermore, decreased proliferative activity of T cells after vaccination will 
reduce vaccine efficacy that is known to be suboptimal in older subjects [6]. However, there is 
confusion as to what senescence in the immune system actually refers to. In some studies the 
overall decline in immune function during ageing that involves both the innate and adaptive 
arms of the immune system, has been termed “immunosenescence” [21]. However, this term 
does not address specifically the characteristics of individual lymphocytes, and it is a 
misconception to assume that the function of all leukocytes are decreased during ageing. In this 
article and in other studies [22-25], T cell senescence refers to the low proliferative activity that 
results from excessive telomere erosion or DNA damage. 
 
Senescent fibroblasts that are generated by continuous culture until they reach the Hayflick limit 
stop proliferating but are still metabolically active and perisist as long as they are supplied with 
nutrients in vitro [7, 26]. These cells have short telomeres, high activity of the enzyme 
galactosidase, show high expression of the DNA repair complex associated protein H2Ax 
and constitutive activation of p53 and p38 map kinase (p38 MAPK), as well the cyclin inhibitor 
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p16 [9, 27] (Table 1).  Within primary human T cells, in both CD4+ [23, 28, 29] and CD8+ [25, 30] 
populations, there is a subset of poorly proliferative cells that exhibit characteristics that are very 
similar to senescent fibroblasts (Fig. 1). These cells can be identified by surface marker 
expression (CD27-,CD28-, CD45RA+, KLRG1+, CD57+) that are all characteristics of highly 
differentiated T cells [23, 28, 30, 31]. Unlike senescent fibroblasts however, T cells that have 
characteristics of senescence are prone to apoptosis in vitro [23, 28] although they may be 
induced to persist by appropriate signals such as growth factors in vivo [32]. An important 
observation is that T cells within both CD4+ and CD8+ compartments that have senescent 
characteristics increase during ageing [25, 33-38] and are therefore likely to have an impact on 
altered immune function in older individuals. Furthermore, persistent infection with viruses 
including cytomegalovirus (CMV) and human immunodeficiency virus (HIV) can induce the 
accumulation of senescent T cells with all the characteristics described above, compared to  
age matched seronegative donors [34, 39, 40].  Although this article focuses on the senescence 
of human T cells, this process may also govern the proliferation and function of other 
lymphocytes such as B cells and innate lymphoid cells during ageing but this remains to be 
investigated. 
 
The secretory nature of senescent cells 
An unexpected property of senescent fibroblasts was their ability to secrete a wide array of pro-
inflammatory cytokines including IL-6 and IL-1 and also other biological mediators such as 
matrix metalloproteinases [41]. This is known as the senescence associated secretory 
phenotype or SASP and is considered to be important for remodelling of ageing tissues [41, 42]. 
In addition, the secretion of chemoattractants including IL-8 and MIP-1 recruit immune cells to 
ageing tissue [18] and recent evidence indicates that NK cells can recognize and eliminate 
senescent cells in vivo [43, 44]. Furthermore, the elimination of senescent cells in a progeroid 
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mouse model can reduce age related pathology in many tissues [45]. The SASP may therefore 
also direct immune cells towards senescent cells in tissues to facilitate their removal. Although 
the growth promoting, tissue remodelling and senescent cell surveillance inducing activity of the 
SASP may be beneficial to maintain the integrity of ageing tissue, it is also associated with the 
development of malignancy [46].  
 
Senescent T cells within both CD4+ and CD8+ subsets express high levels of intracellular 
granules containing the cytotoxic proteins perforin and granzyme B and can mediate 
spontaneous antigen-specific cytotoxicity against infected target cells [47-49]. In comparison to 
less differentiated populations, senescent T cells also secrete high levels of inflammatory 
cytokines such IFN and TNF after short term activation [28, 30, 50] and also matrix 
metalloproteinase (Henson SM and Akbar AN, unpublished observations). Therefore, senescent 
T cells may have an adaptation of the SASP as they are non-proliferative but have a high 
capacity for secreting immune active mediators.  While the SASP in fibroblasts that may be 
involved with tissue re-modelling, the secretory characteristics of senescent T cells are involved 
with immune effector functions (Table 1). Therefore, cell type-specific secretory characteristics 
of senescent cells may be specifically adapted to control different biological processes.  
 
How can we detect senescent T cells? 
The emerging importance of T cell senescence in the maintenance of immunity during ageing 
and also the role of the immune system in the elimination of senescent cells in tissues has 
necessitated the development of new technology to identify senescent cells both within and 
outside the immune system. In T cells, telomere length can be assessed by measuring telomere 
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restriction fragments (TRF) after restriction enzyme digestion of DNA and by qPCR (Q-FISH) 
[51]. However, these techniques are labour intensive, display variation between batches and 
require large amounts of DNA and prior subset isolation [51]. Combining flow cytometry with 
fluorescent in-situ hybridisation (flow-FISH) provides a quick and reproducible technique for 
telomere length analysis using a flurochrome-labelled telomere probe together with surface and 
intracellular parameter staining of different leukocyte populations [34, 52, 53]. The flow-FISH 
technique has been refined to enable the investigation of telomere length, surface phenotype 
and cytokine production in individual T cells [54] within a mixed cell population. This obviates 
the need for the isolation of specific subsets of cells and increases the extent of information that 
can be obtained from small samples of blood [54] or other biological samples.  
 
For T cells in peripheral blood, there is a correlation between the sequential loss of co-
stimulatory receptors on the cell surface and the progressive loss of telomeres. While 
undifferentiated T cells that have relatively long telomeres are CD27+CD28+, senescent T cells 
with the shortest telomeres are found within the CD27-CD28- population [22, 28, 34, 54]. CD4+ T 
cells at an intermediate stage of differentiation are CD27-CD28+, while CD8+ T cells at a similar 
stage are CD27+CD28-, and both these populations have intermediate telomere lengths. The 
highly differentiated CD27-CD28- population of T cells can be further divided and the cells that 
re-express CD45RA within this subset have multiple characteristics of senescence including 
loss of telomerase activity, DNA damage, high levels of reactive oxygen species (ROS)  and the 
lowest proliferative capacity [25, 30]. Intriguingly, the CD45RA re-expressing senesecent T cells 
do not have critically short telomeres suggesting that senescence in these cell may be induced 
by other mechanisms including DNA damage by increased ROS production [25, 30].  
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To identify senescent cells in histological section by immunocytochemistry or 
immunofluorescence, the most common markers used are senescence associated 
galactosidase (SAgal) expression, the cyclin inhibitor p16/INK or the DNA damage 
response protein H2AX however these techniques are rarely combined [55]. A new technique 
for the robust detection of senescent cells combines the staining for DNA Damage foci within 
telomere [56]. Ultimately, to investigate the targeting of senescent cells within tissues by the 
immune system a multiparameter panel of markers for the simultaneous identification of both 
leukocytes as well as the senescent population will be required.  
 
T cell senescence is maintained by active signalling and is reversible  
Until recently, it was not clear if the low proliferative potential and the loss of ability to up-
regulate telomerase activity after activation was a passive response due cellular dysfunction, or 
an actively maintained process involving the activation of inhibitory pathways. It was shown that 
senescent fibroblasts have constitutively activated p38 MAPkinase and the inhibition of this 
enzyme revives the proliferative activity of these cells [57, 58]. This was an early indication that   
senescence was an actively maintained and not passive process. However fibroblasts, unlike T 
cells, do not exhibit telomerase activity [59]. These observations led to investigation of whether 
human senescent T cells, that also exhibit constitutive p38 MAPK activation, could be induced 
to proliferate upon p38 blockade. Using small molecule inhibitors [23, 30] or specific inhibitory 
shRNA [24] it was found that p38 inhibition reconstituted proliferation and also telomerase 
activity in T cells after activation. Therefore the reduced proliferative activity in senescent T cells 
is an actively maintained process that is induced by the engagement of specific inhibitory 
signalling pathways. This raised the question of how p38 was activated in senescent T cells in 
the first place.  
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Two separate pathways for p38 MAPK activation in T cells had been previously described [24, 
60]. The canonical MAPK cascade relies on a cascade of upstream kinases, activated by 
cytokines or co-stimulatory receptor engagement, that phosphorylate and activate downstream 
kinases culminating ultimately in p38 activation. In this context, inflammatory cytokines such as 
IFN-, can activate p38 in non-senescent T cells and this can inhibit proliferation and 
telomerase activity [29, 34, 61]. This raises the question of whether p38 is activated in 
senescent T cells by inflammation in vivo? However senescent T cells lose expression of co-
stimulatory receptors such as CD27 and CD28 that activate the canonical pathway nor do they 
express the upstream kinases associated with the canonical pathway suggesting that p38 may 
be activated an alternative mechanism in these cells [24, 60].  
 
An alternative p38 activating pathway that requires TCR ligation that induces p38 activity 
through auto-phosphorylation, independently of upstream canonical MAPK phosphorylation, has 
been described [60]. However, it was found that senescent T cells do not express several 
kinases and scaffold molecules that are involved in this alternative p38 activation pathway and 
are thus unlikely to engage this second pathway for p38 activation [24, 60]. This suggested the 
existence of a third unique mechanism for the activation of p38 in senescent T cells. This third 
p38 activation pathway in T cells was identified recently and involved the activation of a 
molecular complex that contains AMP-responsive protein kinase (AMPK), a low nutrient and 
energy sensor, a scaffold molecule TAB 1 and p38 itself [24] (Fig. 2). This complex induces p38 
activation through auto-phosphorylation. The critical point is that AMPK is not only activated by 
sensing low intracellular glucose but also by endogenous DNA damage (senescence) signalling 
in T cells but also by [24]. This suggests that there is a convergence of senescence and nutrient 
sensing pathways in T cells to activate p38 via AMPK/TAB1. Correspondingly, the inhibition of 
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either AMPK, TAB1 or p38 itself reconstitutes proliferation as well as telomerase activity in the 
senescent T cell population [24]. This provides points for intervention, in addition to targeting 
p38 itself, to enhance the function of senescent T cells. Undoubtedly other pathways that 
regulate the senescence characteristics of T cells will be identified in due course.  
 
Metabolism of senescent human T cells  
 The regulation of senescent T cell function by senescence and nutrient sensing raises the 
question of how senescent T cells obtain their energy for survival and secretory functions how 
additional energy is obtained for proliferation after blocking the p38 pathway. It was shown that 
human senescent CD8+ T cells preferentially utilise glycolysis to generate ATP, as opposed to 
the effector memory subset which are much more metabolically flexible and can either 
glycolysis or oxidative phosphorylation (OXPHOS) for functional activities (Fig. 3). Senescent 
CD8+ T cells exhibit mitochondrial dysfunction, increased production of reactive oxygen species 
(ROS) and impaired mitochondrial biogenesis, which may explain their dependence on 
glycolysis for energy [25]. The lack of mitochondrial biogenesis may well be a consequence of 
the failure of senescent T cells to activate mTOR (mammaliam target of rapamycin), a central 
integrator of immune signalling and cell metabolism [62], as  demonstrated by their inability to 
phosphorylate the mTOCR1 [25] or the mTORC2 complex [63].  mTOR regulates multiple 
processes, including autophagy, a degradation pathway that removes damaged or unwanted 
organelles as well as providing metabolites during periods of starvation [64]. It has been 
postulated that the decline in autophagy during ageing is due to increased mTORC1 activity. 
However senescent CD8+ T cells displayed both low autophagic activity [25, 65] and also lack 
mTORC1 activity [25]. This suggests that the decreased autophagy in senescent T cells is 
regulated by a different process. Nevertheless, the defective autophagy results in a failure to 
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clear the large giant dysfunctional mitochondria that is linked to increased ROS production by 
senescent CD8+ T cells [25].  
 
Since the blockade of p38 increases the proliferation of senescent T cells, it raises the question 
of how the energy for this enhanced activity is derived. It was found that the p38 signalling 
inhibited autophagy in senescent T cells, a non-canonical mTORC1 independent process, that 
occurs instead via a mechanism that involved increased trafficking of the autophagy regulating 
protein Atg9 from the endosomes to the lysosomes [25]. Blocking p38 enhanced autophagy, 
increased mitochondrial biogenesis, cleared dysfunctional mitochondria and reduced ROS 
production in senescent CD8+ T cells [25] indicating an overall improvement of mitochondrial 
fitness. However despite the increased mitochondrial function, senescent T cells still 
preferentially utilize glycolysis and not OXPHOS for increased proliferation after p38 blockade. 
Furthermore, the recycling of metabolic precursors resulting from increased autophagy and not 
greater glucose uptake fuels the enhanced proliferative activity of senescent T cells after p38 
inhibition. These results reinforce the observations that senescence and nutrient sensing 
pathways are inextricably linked and control the function of T cells.  
  
Inflammation and senescence 
Cellular senescence can cause chronic inflammation through the SASP and this chronic non-
microbial (sterile) inflammation is thought to be the prime cause of many age-related disorders 
such as atherosclerosis, autoimmunity, cancers and dementias [42]. Recent investigations have 
been focused on defining the relationship between inflammageing (association between ageing 
and increased inflammation) and inflammatory disease [66]. Several studies have reported a 
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link between senescence-associated inflammation and a 2-4 fold rise in the levels of acute-
phase markers, such as C-reactive protein, VCAM-1 and IL-6 [67]. Many inflammatory disease 
states exhibit a shortening of telomeres in peripheral blood leukocytes. A meta-analysis of 27 
studies on 13 different cancers found a significant inverse correlation between immune cell 
telomere length and cancer incidence [68]. In addition, epidemiological studies showed an 
increased telomere shortening among patients with cardiovascular disease, atherosclerosis, 
and myocardial infarction [69]. These studies are correlative with no information as to whether 
telomere shortening increases the disease risk or whether short telomeres are a secondary 
consequence of chronic systemic inflammation associated with all these diseases [69]. The fact 
that inflammatory cytokines such as IFN can inhibit telomerase in T cells and induce telomere 
erosion in these cells [29, 34, 61] lends support to the latter possibility.  Molecular studies in 
rheumatoid arthritis have identified alternative defects affecting telomeric stability. It was found 
that T cells from rheumatoid patients accumulate DNA double strand breaks in non-telomeric 
DNA, indicating more generalised abnormalities in sensing, repairing and tolerating broken DNA 
[67]. Furthermore healthy individuals carrying the HLA-DR4 haplotype share with rheumatoid 
patients the age-inappropriate telomere loss, implying that there is a genetic mechanisms in the 
premature deterioration of chromosomal ends [70]. Collectively, these data suggest that in 
addition to a link between nutrition and senescence signalling pathways (Figs 2, 3), 
inflammation related pathways may be a third interacting axis that is involved in controlling of 
the function of senescent T cells.   
 
Implications of blocking senescence by targeting p38 to enhance immunity 
The emerging picture is that senescence in T cell is actively regulated and that by blocking cell 
signalling pathways, the inhibition of proliferation and also telomerase activity in these cells can 
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be reversed. The question that arises is whether p38 blockade to alter T cell function would be 
beneficial or dangerous in vivo. One target for reversing senescence in T cells would be the p38 
MAP kinase pathway and based on data that has been obtained in vitro, blocking agents to p38 
could be used in vivo to enhance certain T cell functions [23-25, 30]. However since the process 
of cellular senescence is considered to be a mechanism to safeguard against malignancy by 
preventing the excessive proliferation of cells with either short telomeres or damaged DNA [8], 
the possible danger is that the inhibition of senescence may promote cancer. Serendipitously, 
many pharmaceutical companies have already tested small molecule p38 inhibitors in humans 
in vivo in phase I,II and II trials to block inflammatory cytokine production in diseases that 
include rheumatoid arthritis, chronic obstructive pulmonary disease and diabetes [71]. Clinical 
trials with p38 inhibitors in patients indicate two important points; first that it is safe in the short 
term (weeks) to treat humans in vivo with p38 inhibitors without a risk of malignancy [71]. 
However senescent T cell function was not tested before or after treatment with these drugs. 
These trials have thus far been unsuccessful and were discontinued because of hepatotoxicity 
after long term treatment (>3 months) and also adaptation of cell signalling pathways leading to 
reduced drug efficacy [72].  Therefore certain drugs that may target T cell senescence may 
have already been developed for clinical use and it may be feasible to treat older humans 
safely, at least in the short term, to boost immunity.  
 
The existence of at least three different p38 activation pathways in T cells (‘Canonical’, 
‘Alternative’ and the recently identified AMPK/TAB1 mode) indicates that additional points for 
intervention to block p38 and thus boost immunity. Since p38 is activated through an 
AMPK/TAB1 dependent pathway in senescent T cells [24], it may be feasible to inhibit target 
one or other of these molecules to block p38 signalling. However AMPK is also a central 
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regulator of cell function and many different cell types including T cells may be affected [73]. 
Therefore AMPK inhibition may have too broad an effect to be therapeutically viable for 
enhancing immunity. Nevertheless a drug that is currently being used to treat type II diabetic 
patients, metformin [74], can activate AMPK  although it is not known if this therapy affects T 
cell function in these patients. Of note, metformin was shown to enhance T cell memory 
generation in mice when administered after primary immunization [75]. However, AMPK 
activation also strongly inhibits effector T cell responses [24]. Thus, AMPK seems to boost 
memory T cell generation but may impede effector T cell responses needed for primary 
immunisation, which is essential for boosting an immune response in old people i.e. for 
influenza vaccination. Regarding T cell senescence, a more selective way to inhibit p38 would 
be to blocking the scaffold molecule TAB1 required for p38 activation in senescent cells, 
however, further studies are required to indicate the feasibility of this. Moreover, blocking the 
p38 pathway can only rescue certain features of T cell senescence. A global approach for 
boosting immunity by targeting multiple MAP kinases during ageing currently under investigation 
(Lanna and Akbar, unpublished findings).  
 
Possible situations where inhibiting senescence could enhance immunity 
One situation where blocking the p38 pathway may be advantageous is during vaccination. The 
efficacy of many vaccines is reduced in older subjects [6] and the short-term blockade of p38 
may open a therapeutic window for enhancement of antigen-specific T cell proliferation, that 
would increase the number of antigen specific cells. This increase is considered to be one of the 
end-points of successful vaccination [76].  Another situation for immune enhancement induced 
by p38 blockade may be in tumour immunotherapy. T cell proliferation and function can also be 
enhanced by blocking signalling through the inhibitory receptors such as PD-1 [77].  This has 
14 
 
been exploited in the therapy of tumours, especially melanoma, where PD1 blockade in patients 
enhances tumour eradication by T cells and improves the survival of these patients [78]. The 
pathway involved in PD1 engagement in senescent human T cells is different for that induced 
by p38 MAP signalling as there is an additive enhancement of proliferation when both PD1 and 
p38 pathways are blocked simultaneously [30]. Therefore it may be possible to manipulate 
senescence signalling pathways in conjunction with other signalling pathways to enhance T cell 
function. While this may be beneficial for older humans, who have decreased overall immunity, 
it may also be useful for the treatment of patient with malignancy.  
It is well recognized that tumours grow even when there are large numbers of T cells 
surrounding or infiltrating them, indicating impaired T-cell killing activity in situ. Recent studies 
showed indeed that tumour infiltrating lymphocytes (TILs) possess attributes of glucose-
deprived cells resulting in T cell dysfunction [79]. Strikingly, administration of blocking antibodies 
to CTLA4/PD1 can restore glucose metabolism in mouse TILs contributing to tumour eradication 
[80]. This indicates that T cell activity is actively inhibited within the tumour microenvironment, in 
part through the engagement of inhibitory receptor signalling that leads to metabolic 
remodelling. Another possible mechanism of cancer-mediated immunosuppression is the 
induction of T regulatory cells (Tregs), an inhibitory T cell population, highly represented at the 
tumour site and characterized by AMPK-dependent metabolic requirements [80]. An exciting 
possibility for tumour persistence despite the presence of T cells is that the tumour-driven 
deprivation of glucose would trigger the AMPK/TAB1 pathway for p38 activation even in non-
senescent T cells. The ‘Intra-Sensory’ activated p38 would in turn restrict T cell responses. 
Since senescence and nutrient sensing signals converge to activate AMPK [24], it may be 
possible to perform nutrient manipulation as well as anti-senescence therapy to promote anti-
tumour activity by T cells. Future work is needed to investigate the role of T cell senescence in 
cancer, and to characterize the metabolic landscape of TILs especially in humans.  
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Nutrient deprivation pathways may also be targetable for boosting responsiveness to 
vaccination in malnourished individuals, for instance in 3rd world countries. Immune-activation is 
an energy-demanding process, and it is thus possible that diminished immune function in such 
individuals may be direct consequence of activation of AMPK-dependent mechanisms. 
Correspondingly, increased risks for opportunistic infections affect third world populations. This 
also opens for possible drug-free interventions to boost immune-responsiveness and implement 
cost-effective, pan-immunization profiles in these people. Simple and immediate interventions, 
i.e. addition of glucose to vaccine formulations, may unveil potent yet underestimated immune-
stimulatory effects disrupting AMPK activation and allowing vaccination of malnourished 
subjects. In the future, exploring nutrient-based strategies and other food-related changes in 
dietary intake either alone or in combination with drug-based interventions may be a cost 
effective way to cope with large-scale immunizations.  
 
Future perspectives  
There is an increasing need to understand how cellular processes,  that are usually investigated 
in isolation from each other, are linked. A case in point is the new awareness of the 
interrelationship between senescence, nutrition and inflammation in regulating T cell function 
[25, 29, 61]. Although a supramolecular complex containing AMPK, TAB1 and p38 is involved in 
regulating the function of senescent T cells, it is possible that this complex also contains other 
molecules that may be targeted to alter T cell function.  This raises the question of whether 
other cellular processes also feed into this interactive network. A key unanswered question is 
whether the same pathways are linked and control the function of other leukocytes and also 
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cells outside the immune system in the same way. The fact that telomere erosion in leukocytes 
correlates with the severity of a vast array of disease states that are associated with many 
different cell types/organs suggests that this may be the case.  A crucial requirement would be 
the identification of an appropriate animal model for testing interventions, using clinically tested 
drugs that are already available to target senescent T cells boost immunity as ethical constraints 
preclude most of such studies in humans. Nevertheless the key message at present is that the 
reduced proliferative function of senescent primary human T cells that accumulate during 
ageing is globally controlled by divergent interacting pathways that may be reversible.  
17 
 
References 
1. Akbar, A.N. et al. (2004) Will telomere erosion lead to a loss of T-cell memory? Nat Rev 
Immunol 4, 737-743 
2. Nikolich-Zugich, J. and Rudd, B.D. (2010) Immune memory and aging: an infinite or 
finite resource? Curr Opin Immunol 22, 535-540 
3. Brien, J.D. et al. (2009) Key role of T cell defects in age-related vulnerability to West Nile 
virus. J Exp Med 206, 2735-2745 
4. Whitehorn, J. and Simmons, C.P. (2011) The pathogenesis of dengue. Vaccine 29, 
7221-7228 
5. Gupta, M. et al. (2004) Persistent infection with ebola virus under conditions of partial 
immunity. J Virol 78, 958-967 
6. Grubeck-Loebenstein, B. et al. (2009) Immunosenescence and vaccine failure in the 
elderly. Aging Clin Exp Res 21, 201-209 
7. Hayflick, L. and Moorhead, P.S. (1961) The serial cultivation of human diploid cell 
strains. Exp Cell Res 25, 585-621 
8. Campisi, J. (2005) Senescent cells, tumor suppression, and organismal aging: good 
citizens, bad neighbors. Cell 120, 513-522 
9. von Zglinicki, T. et al. (2005) Human cell senescence as a DNA damage response. 
Mech Ageing Dev 126, 111-117 
10. Blasco, M.A. (2002) Telomerase beyond telomeres. Nat Rev Cancer 2, 627-633 
11. Weng, N.P. (2008) Telomere and adaptive immunity. Mech Ageing Dev 129, 60-66 
12. Akbar, A.N. and Henson, S.M. (2011) Are senescence and exhaustion intertwined or 
unrelated processes that compromise immunity? Nat Rev Immunol 11, 289-295 
13. Plunkett, F.J. et al. (2005) The impact of telomere erosion on memory CD8+ T cells in 
patients with X-linked lymphoproliferative syndrome. Mech Ageing Dev 126, 855-865 
14. Chung, H.K. et al. (2005) Extratelomeric functions of telomerase. Curr Mol Med 5, 233-
241 
15. d'Adda di Fagagna, F. (2008) Living on a break: cellular senescence as a DNA-damage 
response. Nat Rev Cancer 8, 512-522 
16. Ben-Porath, I. and Weinberg, R.A. (2005) The signals and pathways activating cellular 
senescence. Int J Biochem Cell Biol 37, 961-976 
17. Baker, D.J. et al. (2016) Naturally occurring p16(Ink4a)-positive cells shorten healthy 
lifespan. Nature 530, 184-189 
18. van Deursen, J.M. (2014) The role of senescent cells in ageing. Nature 509, 439-446 
19. Beverley, P.C.L. (2010) Immune Memory: the Basics and How to Trigger an Efficient 
Long-Term Immune Memory. J Comp Pathol 142, Supplement 1, S91-S95 
20. Ahmed, R. and Gray, D. (1996) Immunological Memory and Protective Immunity: 
Understanding Their Relation. Science 272, 54-60 
21. Franceschi, C. et al. (1999) Biomarkers of immunosenescence within an evolutionary 
perspective: the challenge of heterogeneity and the role of antigenic load. Exp Gerontol 
34, 911-921 
22. Plunkett, F.J. et al. (2007) The loss of telomerase activity in highly differentiated 
CD8+CD28-CD27- T cells is associated with decreased Akt (Ser473) phosphorylation. J 
Immunol 178, 7710-7719 
23. Di Mitri, D. et al. (2011) Reversible Senescence in Human CD4+CD45RA+CD27- 
Memory T Cells. J Immunol 187, 2093-2100 
24. Lanna, A. et al. (2014) The kinase p38 activated by the metabolic regulator AMPK and 
scaffold TAB1 drives the senescence of human T cells. Nat Immunol 15, 965-972 
18 
 
25. Henson, S.M. et al. (2014) p38 signaling inhibits mTORC1-independent autophagy in 
senescent human CD8+ T cells. J Clin Invest 124, 4004-4016 
26. Blagosklonny, M.V. (2011) Cell cycle arrest is not senescence. Aging 3, 94-101 
27. Freund, A. et al. (2010) Inflammatory networks during cellular senescence: causes and 
consequences. Trends in Molecular Medicine 16, 238-246 
28. Libri, V. et al. (2011) Cytomegalovirus infection induces the accumulation of short-lived, 
multifunctional CD4+CD45RA+CD27+ T cells: the potential involvement of interleukin-7 
in this process. Immunology 132, 326-339 
29. Lanna, A. et al. (2013) IFN-alpha inhibits telomerase in human CD8(+) T cells by both 
hTERT downregulation and induction of p38 MAPK signaling. J Immunol 191, 3744-
3752 
30. Henson, S.M. et al. (2015) Blockade of PD-1 or p38 MAP kinase signaling enhances 
senescent human CD8(+) T-cell proliferation by distinct pathways. Eur J Immunol 45, 
1441-1451 
31. Henson, S.M. et al. (2009) KLRG1 signaling induces defective Akt (ser473) 
phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. Blood 
113, 6619-6628 
32. Waller, E.C. et al. (2007) Differential costimulation through CD137 (4-1BB) restores 
proliferation of human virus-specific "effector memory" (CD28(-) CD45RA(HI)) CD8(+) T 
cells. Blood 110, 4360-4366 
33. Appay, V. et al. (2007) Accelerated immune senescence and HIV-1 infection. Exp 
Gerontol 42, 432-437 
34. Fletcher, J.M. et al. (2005) Cytomegalovirus-specific CD4+ T cells in healthy carriers are 
continuously driven to replicative exhaustion. J Immunol 175, 8218-8225 
35. Hamann, D. et al. (1997) Phenotypic and functional separation of memory and effector 
human CD8+ T cells. J Exp Med 186, 1407-1418 
36. Khan, N. et al. (2002) Cytomegalovirus seropositivity drives the CD8 T cell repertoire 
toward greater clonality in healthy elderly individuals. J Immunol 169, 1984-1992 
37. Das, A. et al. (2008) Functional skewing of the global CD8 T cell population in chronic 
hepatitis B virus infection. J Exp Med 205, 2111-2124 
38. Hoare, M. et al. (2010) CD4+ T-lymphocyte telomere length is related to fibrosis stage, 
clinical outcome and treatment response in chronic hepatitis C virus infection. J Hepatol 
53, 252-260 
39. Appay, V. et al. (2008) CD8+ T cell efficacy in vaccination and disease. Nat Med 14, 
623-628 
40. Hertoghs, K.M. et al. (2010) Molecular profiling of cytomegalovirus-induced human 
CD8+ T cell differentiation. J Clin Invest 120, 4077-4090 
41. Coppe, J.P. et al. (2010) The senescence-associated secretory phenotype: the dark side 
of tumor suppression. Annual review of pathology 5, 99-118 
42. Tchkonia, T. et al. (2013) Cellular senescence and the senescent secretory phenotype: 
therapeutic opportunities. J Clin Invest 123, 966-972 
43. Krizhanovsky, V. et al. (2008) Senescence of activated stellate cells limits liver fibrosis. 
Cell 134, 657-667 
44. Sagiv, A. et al. (2016) NKG2D ligands mediate immunosurveillance of senescent cells. 
Aging 8, 328-344 
45. Baker, D.J. et al. (2004) BubR1 insufficiency causes early onset of aging-associated 
phenotypes and infertility in mice. Nature genetics 36, 744-749 
46. Coppe, J.P. et al. (2008) Senescence-associated secretory phenotypes reveal cell-
nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 
6, 2853-2868 
19 
 
47. Hislop, A.D. et al. (2007) Cellular responses to viral infection in humans: lessons from 
Epstein-Barr virus. Annu Rev Immunol 25, 587-617 
48. Dunne, P.J. et al. (2005) Quiescence and functional reprogramming of Epstein-Barr 
virus (EBV)-specific CD8+ T cells during persistent infection. Blood 106, 558-565 
49. Long, H.M. et al. (2011) Cytotoxic CD4+ T Cell Responses to EBV Contrast with CD8 
Responses in Breadth of Lytic Cycle Antigen Choice and in Lytic Cycle Recognition. The 
Journal of Immunology 187, 92-101 
50. Dunne, P.J. et al. (2002) Epstein-Barr virus-specific CD8(+) T cells that re-express 
CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood 
100, 933-940 
51. Montpetit, A.J. et al. (2014) Telomere length: a review of methods for measurement. 
Nursing research 63, 289-299 
52. Baerlocher, G.M. et al. (2006) Flow cytometry and FISH to measure the average length 
of telomeres (flow FISH). Nature protocols 1, 2365-2376 
53. Rufer, N. et al. (2003) Ex vivo characterization of human CD8+ T subsets with distinct 
replicative history and partial effector functions. Blood 102, 1779-1787 
54. Riddell, N.E. et al. (2015) Multifunctional cytomegalovirus (CMV)-specific CD8(+) T cells 
are not restricted by telomere-related senescence in young or old adults. Immunology 
144, 549-560 
55. de Jesus, B.B. and Blasco, M.A. (2012) Assessing Cell and Organ Senescence 
Biomarkers. Circulation research 111, 97-109 
56. Hewitt, G. et al. (2012) Telomeres are favoured targets of a persistent DNA damage 
response in ageing and stress-induced senescence. Nat Commun 3, 708 
57. Passos, J.F. et al. (2010) Feedback between p21 and reactive oxygen production is 
necessary for cell senescence. Mol Syst Biol 6, 347 
58. Davis, T. et al. (2010) Evaluating the role of p38 MAP kinase in growth of Werner 
syndrome fibroblasts. Ann N Y Acad Sci 1197, 45-48 
59. Cong, Y.-S. et al. (2002) Human Telomerase and Its Regulation. Microbiology and 
Molecular Biology Reviews 66, 407-425 
60. Salvador, J.M. et al. (2005) Alternative p38 activation pathway mediated by T cell 
receptor-proximal tyrosine kinases. Nat Immunol 6, 390-395 
61. Reed, J.R. et al. (2004) Telomere erosion in memory T cells induced by telomerase 
inhibition at the site of antigenic challenge in vivo. J Exp Med 199, 1433-1443 
62. Powell, J.D. et al. (2012) Regulation of immune responses by mTOR. Annu Rev 
Immunol 30, 39-68 
63. Franzese, O. et al. (2014) Defect in HSP90 expression in highly differentiated human 
CD8+ T lymphocytes. Cell Death Dis 5, e1294 
64. Terman, A. and Brunk, U.T. (2005) The aging myocardium: roles of mitochondrial 
damage and lysosomal degradation. Heart, lung & circulation 14, 107-114 
65. Phadwal, K. et al. (2012) A novel method for autophagy detection in primary cells: 
impaired levels of macroautophagy in immunosenescent T cells. Autophagy 8, 677-689 
66. Franceschi, C. et al. (2000) Inflamm-aging. An evolutionary perspective on 
immunosenescence. Ann N Y Acad Sci 908, 244-254 
67. Hohensinner, P.J. et al. (2011) Telomere Dysfunction, Autoimmunity and Aging. Aging 
and disease 2, 524-537 
68. Wentzensen, I.M. et al. (2011) The Association of Telomere Length and Cancer: A Meta-
Analysis. Cancer Epidemiol Biomarkers Prev 20, 1238-1250 
69. Chou, J.P. and Effros, R.B. (2013) T cell replicative senescence in human aging. Current 
pharmaceutical design 19, 1680-1698 
20 
 
70. Schönland, S.O. et al. (2003) Premature telomeric loss in rheumatoid arthritis is 
genetically determined and involves both myeloid and lymphoid cell lineages. Proc Natl 
Acad Sci U S A 100, 13471-13476 
71. Patterson, H. et al. (2014) Protein kinase inhibitors in the treatment of inflammatory and 
autoimmune diseases. Clinical & Experimental Immunology 176, 1-10 
72. Sweeney, S.E. (2009) The as-yet unfulfilled promise of p38 MAPK inhibitors. Nature 
reviews. Rheumatology 5, 475-477 
73. Ho, P.-C. and Liu, P.-S. (2016) Metabolic communication in tumors: a new layer of 
immunoregulation for immune evasion. Journal for Immunotherapy of Cancer 4, 4 
74. Viollet, B. et al. (2012) Cellular and molecular mechanisms of metformin: an overview. 
Clinical Science (London, England : 1979) 122, 253-270 
75. Pearce, E.L. et al. (2009) Enhancing CD8 T-cell memory by modulating fatty acid 
metabolism. Nature 460, 103-107 
76. Wherry, E.J. et al. (2005) Low CD8 T-cell proliferative potential and high viral load limit 
the effectiveness of therapeutic vaccination. J Virol 79, 8960-8968 
77. Riella, L.V. et al. (2012) Role of the PD-1 Pathway in the Immune Response. Am J 
Transplant 12, 2575-2587 
78. Mahoney, K.M. et al. (2015) Combination cancer immunotherapy and new 
immunomodulatory targets. Nat Rev Drug Discov 14, 561-584 
79. Pearce, E.L. and Pearce, E.J. (2013) Metabolic pathways in immune cell activation and 
quiescence. Immunity 38, 633-643 
80. Ho, P.-C. et al. (2015) Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T 
Cell Responses. Cell 162, 1217-1228 
 
21 
 
Figure 1. Differences in the manifestation of senescence in T cells and fibroblasts.  
The majority of data on cellular senescence has been performed on fibroblasts, T cells also 
undergo senescence in a similar but not identical manner. Both cell types respond similarly to 
senescence stimuli by inducing a DNA damage response, associated with temporary growth 
arrest. If this DNA damage cannot be repaired a state of deep irreversible senescence ensues. 
T cells however are susceptible to apoptosis and die before they reach this stage whereas 
fibroblasts can remain for long periods in a non-proliferative state. Reviewed in [9, 15].  
 
Figure 2. AMPK activates p38 MAPK in senescent T cells. 
The canonical MAPK cascade is the main mechanism for activation of p38 in mammalian cells, 
including T cells. However senescent T cells have an engage a distinct mechanism, whereby 
under low nutrient conditions p38 is phosphorylated via AMPK and the scaffold protein TAB1β, 
an isoform only expressed in senescent T cells. 
 
Figure 3. Senescent T cells lose their metabolic flexibility 
T cells can utilise either OXPHOS or glycolysis to meet their energy requirements. However 
senescent CD8+ T cells display a profound mitochondrial dysfunction causing the cells to switch 
to glycolysis in order to fuel their effector functions. This metabolic switch renders the senescent 
CD8+ T cells metabolic unstable.  
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Table 1. Characteristics of fibroblast vs T cell senescence.  
The majority of data on cellular senescence has been performed on fibroblasts, T cells also 
undergo senescence in a similar but not identical manner. The key features of the senescence 
phenotype are common to fibroblast and T cells, such as the lack of proliferation, short 
telomeres and the inability to upregulate telomerase. However a major difference is the 
susceptibility to apoptosis with fibroblasts being long lived and T cells succumbing to death by 
apoptosis. Furthermore it is not known whether senescent T cells express high levels of -
galactosidase or H2AX. For reviews see [1, 15] 
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